BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr
X-WR-CALDESC:Évènements pour Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231030T113000
DTEND;TZID=Europe/Paris:20231030T113000
DTSTAMP:20260430T054520
CREATED:20230801T075849Z
LAST-MODIFIED:20231025T175545Z
UID:161710-1698665400-1698665400@www.bordeaux-neurocampus.fr
SUMMARY:Seminar - Ivan D. Montoya
DESCRIPTION:Venue: Centre Broca \n\nIvan Montoya\nNational Institute of Drug Abuse (Maryland\, United States)\nDirector\nhttps://www.researchgate.net/profile/Ivan-Montoya-8 \nInvited by Marc Auriacombe \nTitle\nNew targets and medications for stimulant use disorders \nAbstract\nThe prevalence of stimulant use disorders (StUD) is increasing worldwide. In the United States\, stimulants are associated with about 40% of the drug overdose deaths. Unfortunately\, there are no medications approved by regulatory agencies to treat StUD\, including stimulant overdose. The US National Institute on Drug Abuse (NIDA) has intensified its efforts to discover and develop medication to tear these conditions. The purpose of the presentation is to provide an overview of the new pharmacological targets and new medications that NIDA is currently investigating to treat StUD and overdose. \nBiosketch\nDr. Montoya is the Clinical Director of the Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA) and Chair of the National Institutes of Health (NIH) HEAL Initiative in Therapeutics Development for Opioid and Stimulant Use Disorders. He leads a large program of research that supports the development of pharmacological and non-pharmacological treatments for Substance Use Disorders (SUDs). He has an M.D. and specialized in psychiatrist from the University of Antioquia (Colombia) and has a Master’s in Public Health (M.P.H.) from Johns Hopkins University. He completed a Post-Doctoral Fellowship at the Intramural Research Program of NIDA and was the Director of the Practice Research Network of the American Psychiatric Association. He has published extensively in the areas of etiology\, prevention\, treatment\, and medical consequences of SUDs. He is the editor of a book summarizing the science on biologics (vaccines\, monoclonal antibodies\, and enzymes) to treat SUDs and of another book focusing on the science of Cannabis Use Disorders. He has received numerous awards including the NIH Director’s Award and the Michael Morrison Award from the College on Problems of Drug Dependence (CPDD). \n
URL:https://www.bordeaux-neurocampus.fr/event/seminar-ivan-d-montoya/
CATEGORIES:A la une,Pour les scientifiques,Séminaire Impromptu
END:VEVENT
END:VCALENDAR